Influenza Medication Market to Reach $993.7 Million by 2026; Growing Research into the Changing Nature of the Influenza Virus to Fuel the Market: Fortune Business Insights™

The global “influenza medication market” size is projected to reach USD 993.7 million by 2026, exhibiting a CAGR of 2.2% during the forecast period. Increasing global burden of influenza will be one of the central forces driving the growth of this market. Influenza, or the flu, is a virus that infects the human respiratory system, that is, the throat, lungs, and nose. Usually, the infection subsides on its own, but sometimes it can turn severe and even prove to be fatal. According to the World Health Organization (WHO), every year influenza epidemics around the globe affect around 3 million to 5 million people and cause respiratory deaths between 290,000 and 650,000. The developed nations are also bearing the impact of this deadly virus. For instance, the US Centers for Disease Control and Prevention (CDC) states that since 2010, the occurrence of influenza-related illnesses in the US have been between 9 million and 45 million. In 2016-17, the CDC estimates that hospitalizations resulting from influenza alone will be around 500,000. Thus, such exponential rise in the prevalence of this infection will raise the influenza treatment market demand in the coming years. In its new report, titled “Influenza Medication Market Size, Share & Industry Analysis, By Treatment (Baloxavir marboxil, Oseltamivir phosphate, Others), By Influenza Type (Influenza A, Influenza B), By Route of Administration (Oral, Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast, 2019-2026”, Fortune Business Insights™ states that the value of this market stood at USD 889.2 million in 2018. The report also contains:

Exhaustive research into the different market segments;
Comprehensive assessment of the various drivers and challenges influencing the market;
360-degree analysis of the competitive landscape (company profiles, strategies, and product offerings); and
Careful study of the regional dynamics shaping the market.
Request a Sample Copy of the Research Report:

https://www.fortunebusinessinsights.com/enquiry/sample/influenza-medication-market-101843

Rising Threat from Risk Factors for Influenza to Propel the Market

Prominent among the influenza medication market trends is the threats posed by the risk factors inducing or worsening the effects of influenza infection in humans. According to the CDC, the people most at risk for flu complications include pregnant women, diabetics, asthmatics, adults aged 65 or older, young children, HIV/AIDS patients, cancer patients, and people suffering from chronic lung or heart condition.

For example, congestive heart condition in a person can worsen if she contracts the flu infection. The influenza drugs market growth is further bolstered by the rising prevalence of these risk factors. For instance, the WHO estimates that approximately 235 million people worldwide are living with asthma currently, while 18.1 million new cancer cases were reported worldwide in 2018, the WHO states.

An Overview of the Impact of COVID-19 on this Market:

The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.

We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.

Strong Support to R&D Activities to Fuel the Market in North America

North America is anticipated to dominate the influenza medication market share in the forecast period as the region generated a revenue of USD 527.3 million in 2018. Financial and regulatory support to academic institutions and private companies for R&D for studying influenza virus mutations will be the primary growth factor for the market in the region. Other than this, high incidence of different types of influenza along with rising awareness about the disease will also expand the regional market.

Government initiatives, increasing disposable income, and growing awareness about the dangers of the infection will accelerate the influenza medication market revenue in Asia-Pacific. In Europe, influenza research is gathering momentum which is driving the market in the region, while in the Middle East and Africa, availability of subsidized drugs will augment the market.

Quick Buy Influenza Medication Market

https://www.fortunebusinessinsights.com/checkout-page/101843

Regulatory Support to Novel Therapies to Fire up Competition

Major players in this market are intensely engaged in developing new and unique therapies for influenza and regulatory authorities are providing the necessary support to the efforts, according to one of our leading analysts. Not only is this widening consumer choice, but it is also enhancing the market potential, as per the influenza medication market analysis.

Industry Developments:

October 2019: Shionogi & Co., the leading Japanese drug maker, submitted supplemental New Drug Application (sNDA) for Xofluza (baloxavir marboxil) to the Japanese government. The application is based on the company’s Phase III BLOCKSTONE study which evaluated the efficacy of Xofluza in the post-exposure prophylaxis in household members of influenza patients.
March 2019: GlaxoSmithKline announced that it received positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) for the company’s intravenous zanamivir therapy. The therapy is designed to treat influenza A or B infection in adults and children at or below 6 years of age.
Key Players Covered in the Influenza Medication Market Report:

Alvogen
Amneal Pharmaceuticals LLC
Teva Pharmaceutical Industries Ltd.
GlaxoSmithKline plc
Seqirus (CSL)
Genentech, Inc.
Macleods Pharmaceuticals Ltd.
Zydus Pharmaceuticals, Inc. (Zydus Cadila)
Lupin Limited
BIOCRYST PHARMACEUTICALS, INC.
Shionogi & Co., Ltd.
Have Any Query? Ask Our Experts

https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/influenza-medication-market-101843

Table of Content

Introduction
Research Scope
Market Segmentation
Research Methodology
Definitions and Assumptions
Executive Summary
Market Dynamics
Market Drivers
Market Restraints
Market Opportunities
Key Insights
Overview of Influenza Epidemiology
Analysis of Disease Burden of Influenza, By Key Regions
New Product Launches
Pipeline Analysis
Analysis of the Impact of the Launch of Generics on the Influenza Medication Market
Key Industry Developments
Global Influenza Medication Market Analysis, Insights and Forecast, 2015-2026
Key Findings / Summary
Market Analysis, Insights and Forecast – By Treatment
Baloxavir marboxil
Oseltamivir phosphate
Others
Market Analysis, Insights and Forecast – By Influenza Type
Influenza A
Influenza B
Market Analysis, Insights and Forecast – By Route of Administration
Oral
Others
Market Analysis, Insights and Forecast – By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Market Analysis, Insights and Forecast – By Region
North America
Europe
Asia Pacific
Latin America
Middle East & Africa
ToC Continue…
You can Find an In-depth Analysis on “Influenza Medication Market
” by Dr Daniel Stewart Here: https://www.linkedin.com/pulse/telemedicine-promising-technology-healthcare-industry-stewart/

About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.

308, Supreme Headquarters,

Survey No. 36, Baner,

Pune-Bangalore Highway,

Pune - 411045, Maharashtra, India.

Phone:

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email:sales@fortunebusinessinsights.com

Linkedin | Twitter | Blogs

This release was published on openPR.